Since the in vivo anti-tumor efficacy of Akt inhibitor GSK690693 has been shown in mice bearing breast tumor, lymphoma, endometrial tumor, ovarian carcinoma, and osteosarcoma59, 60, we also examined the role of GSK690693 in the treatment of HE in animals. The gene discussed is AKT1; the disease is breast neoplasm.